Magenta Medical Reports the Completion of Patient enrolment in Early Feasibility Study for Elevate Percutaneous Left Ventricular Assist Device
- The patient enrolment has been completed in the US FDA-approved early feasibility study of Elevate percutaneous Left Ventricular Assist Device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication. The study enrolled 15 patients at Mount Sinai Hospital, St. Francis Hospital, and Heart Center, and North Shore University Hospital
- The device focuses to provide temporary mechanical circulatory support during HR-PCI procedures. The technology miniaturizes the powerful, percutaneous LVAD to fit an 8 Fr delivery system
- The device also received Breakthrough Device Designation from the US FDA for high-risk percutaneous coronary intervention and cardiogenic shock
Ref: PR Newswire | Image: Magenta
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.